Cibus 2025 Q3 Earnings 87.9% Net Loss Reduction Amid Revenue Decline

Cibus (CBUS) reported fiscal 2025 Q3 results on Nov 13th, 2025, with a net loss of $24.3 million—down 87.9% from $201.46 million in 2024 Q3—while revenue fell 63.1% to $615,000. The company missed revenue estimates by 43.58% and narrowed per-share losses to $0.44 from $7.63.

Revenue

Total revenue declined sharply to $615,000 in Q3 2025, a 63.1% drop from $1.67 million in the prior-year period. The reduction reflects timing of partner-funded activities and ongoing operational challenges.

Earnings/Net Income

Cibus reduced its net loss to $24.3 million in Q3 2025, representing an 87.9% improvement from the $201.46 million loss in Q3 2024. Earnings per share improved to a loss of $0.44 from $7.63, a 94.2% reduction. Despite progress, the company has posted losses for 10 consecutive years in this quarter.

Post-Earnings Price Action Review

The strategy of buying CBUS shares on earnings report dates and holding for 30 days has underperformed significantly, with a 3-year compound annual return of -46.2%. The maximum drawdown of 51.4% occurred after the latest report, underscoring the stock’s volatility. While brief positive days emerged, sustained underperformance highlights the futility of short-term trading around earnings.

CEO Commentary

Interim CEO Peter Beetham emphasized progress in herbicide tolerance (HT) traits for rice, with seven customer agreements covering 5-7 million acres and $200M+ in potential annual royalties. Strategic partnerships in Latin America and India, including collaborations with CIAT and AgVayā, are pivotal for 2027-2028 commercialization. The CEO also noted $30M in annual cash usage targets by 2026 and regulatory advancements in gene-editing efficiency.

Guidance

Cibus aims to deliver HT traits to Latin American customers by Q4 2025, with field trials commencing by year-end. The company expects initial payments from its Sustainable Ingredients program in Q4 2025 and anticipates reducing annual net cash usage to $30M by 2026. Regulatory progress in the UK, Ecuador, and the U.S. is expected to support global commercialization efforts.

Additional News

Cibus strengthened its board with the appointment of Kimberly Box and Craig Wisner, adding expertise in sustainable agriculture and technology operations. The company also partnered with AgVayā to enter India’s rice market, targeting 120 million acres. Additionally, pre-commercial pilot runs for biofragrance products were completed, positioning the firm for 2026 commercial expansion.